Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

Trials

2024-515163-63-00

EU Clinical Trials Information System

Trial ID
T-ctis-2024-515163-63-00
Registry
EU Clinical Trials Information System
CTIS number
2024-515163-63-00
Asset
psilocybin (investigator-led)
Sponsor, as registered
Region Skane
Phase
Therapeutic exploratory (Phase II)
Indication
Anorexia Nervosa
Status
Authorised
Primary completion
CTIS does not publish one.
Member states concerned
Sweden
Sites
1

Member states whose regulator has a decision on this trial.

euclinicaltrials.euctis registryverified 2026-08-31

Notes on the record

countries is memberStatesConcerned, i.e. every member state the trial is filed in; site_count sums trialSites across authorised Part II sections. primary_completion_date is EMPTY because CTIS does not publish a primary completion date; it is not unknown, it is not a field the registry has. Per-state authorisation is NOT recorded: mscPublicStatusCode takes values [2] on this record and the registry publishes no key for them, so decoding it would be a guess.

Company

Through psilocybin (investigator-led): Region Skane

Cited in

Issues quoting 2024-515163-63-00 in their own text.